Antibiotic Dosing for Community-Acquired Pneumonia in Adults
For healthy outpatient adults with typical community-acquired pneumonia and no comorbidities, prescribe amoxicillin 1 gram three times daily as first-line therapy 1.
Outpatient Treatment Algorithm
Healthy Adults Without Comorbidities
The 2019 ATS/IDSA guidelines provide clear first-line options 1:
- Amoxicillin 1 g three times daily (strong recommendation, moderate quality evidence)
- Doxycycline 100 mg twice daily (conditional recommendation, low quality evidence)
- Macrolide (azithromycin 500 mg day 1, then 250 mg daily; OR clarithromycin 500 mg twice daily; OR clarithromycin ER 1,000 mg daily) - only if local pneumococcal macrolide resistance is <25% (conditional recommendation, moderate quality evidence)
The amoxicillin recommendation reflects the British Thoracic Society approach of using high-dose aminopenicillins to overcome reduced pneumococcal susceptibility while avoiding widespread fluoroquinolone use that drives resistance 2.
Adults With Comorbidities
For patients with chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; or asplenia, use combination therapy or fluoroquinolone monotherapy 1:
Combination therapy options:
- Amoxicillin-clavulanate 500/125 mg three times daily, OR 875/125 mg twice daily, OR 2,000/125 mg twice daily
- OR Cefpodoxime 200 mg twice daily
- OR Cefuroxime 500 mg twice daily
PLUS one of:
- Macrolide (azithromycin 500 mg day 1, then 250 mg daily; OR clarithromycin 500 mg twice daily or ER 1,000 mg daily) - strong recommendation
- OR Doxycycline 100 mg twice daily - conditional recommendation
Fluoroquinolone monotherapy alternative:
- Levofloxacin 750 mg daily
- OR Moxifloxacin 400 mg daily
- OR Gemifloxacin 320 mg daily (Strong recommendation, moderate quality evidence)
Recent network meta-analysis data suggest quinolones and macrolides show trends toward better clinical response, though confidence intervals overlap significantly 3. A 2024 retrospective study found no mortality differences between fluoroquinolone monotherapy, macrolide plus β-lactam, or doxycycline plus β-lactam regimens 4.
Inpatient Treatment (Non-ICU)
For hospitalized patients not requiring ICU admission, the evidence from [@2-10@] addresses hospital-acquired pneumonia but the 2019 CAP guidelines recommend 1, 5, 6:
Standard regimen:
- Respiratory fluoroquinolone (levofloxacin 750 mg IV daily, moxifloxacin 400 mg IV daily)
- OR β-lactam plus macrolide:
- Ceftriaxone 1-2 g IV daily OR cefotaxime 1-2 g IV every 8 hours
- PLUS azithromycin 500 mg IV daily
Severe CAP (ICU Admission)
For patients requiring ICU admission 1, 5, 6:
Mandatory dual therapy:
- β-lactam antibiotic:
- Ceftriaxone 1-2 g IV daily OR cefotaxime 1-2 g IV every 8 hours
- OR ampicillin-sulbactam 1.5-3 g IV every 6 hours
PLUS:
- Azithromycin 500 mg IV daily
- OR respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily)
A 2025 network meta-analysis found β-lactam plus macrolides ranked most effective for severe CAP mortality reduction (RR 0.79 vs β-lactam alone, RR 0.67 vs β-lactam plus fluoroquinolones) 7.
Special Considerations for Severe CAP
Pseudomonas risk factors (structural lung disease, recent broad-spectrum antibiotics):
- Antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, imipenem 500 mg IV every 6 hours, or meropenem 1 g IV every 8 hours)
- PLUS aminoglycoside (gentamicin 5-7 mg/kg IV daily) or antipseudomonal fluoroquinolone
- PLUS azithromycin 5, 6
MRSA risk factors (prior MRSA, recent IV antibiotics, local prevalence >20%):
- Add vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600 mg IV every 12 hours 5, 6
Treatment Duration
The 2025 updated guidelines recommend shorter durations based on clinical stability 8, 9:
- 3 days minimum for outpatients and non-severe hospitalized CAP patients achieving clinical stability by day 3 (rather than ≥5 days)
- 5 or more days for severe CAP requiring ICU admission
- Clinical stability defined as: temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24/min, systolic BP ≥90 mmHg, oxygen saturation ≥90%, ability to take oral medications, normal mental status
This represents a significant shift from previous 5-7 day recommendations, supported by randomized trials demonstrating non-inferiority of 3-day treatment in stabilized patients 9.
Critical Pitfalls to Avoid
Do not use macrolide monotherapy in areas with >25% pneumococcal macrolide resistance - this is increasingly common and leads to treatment failure 1
Do not use fluoroquinolone monotherapy in patients who received fluoroquinolones in the past 3 months - resistance risk is substantial
Do not switch from IV to oral antibiotics until clinical stability is achieved - typically requires 48-72 hours of clinical improvement 5
Do not use β-lactam monotherapy for severe CAP - dual therapy with macrolide or fluoroquinolone is mandatory for mortality benefit 7
Avoid corticosteroids in non-severe CAP - the 2025 guidelines recommend against their use except in severe cases 8, 10